Paratek Pharmaceuticals Inc. CEO Michael Bigham told BioWorld Today “it’s very hard to know at this point” how competitor Cempra Inc. will handle the pricing of late-stage solithromycin for community-acquired bacterial pneumonia (CABP), and what this will mean for omadacycline, which just started a pivotal phase III trial in the same indication.